Navigation Links
Sygnis Pharma AG announces date for presentation of clinical,results

HEIDELBERG, Germany, 11 July 2007 – On 23 July SYGNIS Pharma AG will present the results of the clinical phase IIa study for AX200 (AXIS-study).

AX200, a compound for the treatment of stroke, is the most advanced drug candidate in SYGNIS’ product pipeline. The primary aim of the study is to show safety and tolerability of AX200 in acute stroke patients. The results of the AXIS-study are expected to provide information for the further clinical development of AX200.

Furthermore, the company announces that this year’s Annual General Meeting will take place on 28 November 2007 in Eppelheim.

About SYGNIS Pharma

SYGNIS Pharma AG, with head offices in Heidelberg, is a specialist pharmaceutical company listed on the Prime Standard of the German stock exchange. The company is focusing on the research, development and marketing of innovative therapies for the treatment of neurodegenerative diseases. These include stroke, Amyotrophic Lateral Sclerosis (ALS), Huntington's Disease or neurological disorders resulting from injury, such as trauma of the brain or spinal cord. All these disorders are characterised by the fact that, as the disease progresses, nerve cells die off. Although there is a great medical demand, there are currently no or only inadequate treatment options available.

In its drug development, the company has taken a completely novel approach: it develops compounds that protect nerve cells in the acute phase of the disease, and beyond that, also stimulate the regeneration of the damaged nervous system.

For more information, please contact:

Dr. Franz-Werner Haas Vice President Operations +49 (0) 6221 454 812 franz-werner.haas@sygnis.de

### Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as f
'"/>




Page: 1 2

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sygnis Pharma announces date for presentation clinical results
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
... , , WESTWOOD, Mass., Dec. ... of imaging cytometry instrumentation and the leading supplier of ... state-of-the art iGeneration line of imaging cytometers to include ... With the option of four excitation lasers chosen from ...
... ... is pleased to announce that Alexander von Perfall has ... (Logo: http://www.newscom.com/cgi-bin/prnh/20061026/RPLOGO ) , Alexander has 13 years ... experience, most recently as co-founder and Chief Network Officer ...
Cached Medicine Technology:CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2
(Date:12/25/2014)... Phoenix, AZ (PRWEB) December 25, 2014 ... comes to outstanding customer service and affordable quality regarding ... metropolitan area announces recognition in 2014 by the “Queen ... and Sons has earned an impressive reputation over the ... pricing on a wide range of contractor services for ...
(Date:12/24/2014)... 2014 Connie Casad, MD, a well-known ... advocate with 30 years of practice experience in Dallas, ... health benefits of dietary detoxification. The second study is ... excellent results from test patients who just completed a ... her interest in conducting the study, Dr. Casad said, ...
(Date:12/24/2014)... 2014 Dr. Vu Ho, a Dallas ... his practice and med-spa with the addition of new ... of cosmetic treatments and services. , “Silk Peel is ... says Dr. Ho. “As a result it can address ... sun spots, discolorations or blemishes.” , Similar to microdermabrasion, ...
(Date:12/24/2014)... December 25, 2014 The report “Stivarga ... focuses on the current treatment landscape, unmet needs, current ... Stivarga is a drug which is used in the ... orally administered and is also prescribed to patients who ... is FDA approved is a multi-kinase inhibitor and it ...
(Date:12/24/2014)... holidays can be a challenge for people who suffer migraines, ... "This is the season in which many people overindulge ... Dodick, chair of the American Migraine Foundation, said in a ... through food and beverage choices, to help reduce the risk ... neurology at the Mayo Clinic in Scottsdale, Ariz. , , ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Expert Offers Tips for Preventing Holiday Migraines 2
... at Oregon Health & Science University,s School of Dentistry ... controlling heart rate and blood pressure synthesize a molecule ... growth. The finding could someday play a significant role ... and high blood pressure. According to the National Institutes ...
... Pharmaceuticals today announced that Scott Jackson, chief executive officer, ... in San Francisco. Mr. Jackson will provide a ... development programs. The presentation will be held on ... A of the Marines, Memorial Club & Hotel. About ...
... Mandates Label Accuracy, Truth in Advertising and ... In response to misleading statements recently made ... Association,s Executive Director and CEO, David Seckman, ... leagues on steroid usage, which the Natural ...
... deadly for women and African-Americans, but the reasons long believed ... differences for such patients compared to their white and male ... of the journal Cancer . , The results present ... type, and stage of the disease upon diagnosis don,t account ...
... for Childhood Cancer Research (NCCCR), a newly established division of Nemours ... in Wilmington, DE, has secured $1,020,000 in external funding for awards ... ... January 8, 2009-- The research team at the Nemours Center ...
... may explain linguistic and cultural differences of native peoples , , ... two different waves of people migrated from what is now ... settlers in the Americas, a new report says. , ... came to North America via the Beringia landmass, which once ...
Cached Medicine News:Health News:OHSU School of Dentistry team discovers new molecule in blood-pressure control system 2Health News:Natural Products Association Advocates Strength of Dietary Supplement Law 2Health News:Why bladder cancer is deadlier for some 2Health News:Why bladder cancer is deadlier for some 3Health News:Why bladder cancer is deadlier for some 4Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 2Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 3Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 4Health News:First Americans Arrived on 2 Separate Paths 2
... units with hydrophobic PTFE membranes,Millex filter ... ideal for the sterilizing filtration of ... and for sterilizing or clarifying organic ... filter units are available with different ...
... -4C. 5.5 Cubic Ft. ... light. Manual push button ... Two shelves. In-door shelves ... thermostat. Magnetic gasket. Hermetically ...
... Water, The Simplicity personal water system is ... use bottled water. In addition to the ... bottled water, your laboratory applications may be ... absorbed from containers and cause water quality ...
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory....
Medicine Products: